Midsouth Bancorp Inc (MSL) investors sentiment decreased to 1.89 in Q3 2018. It’s down -0.05, from 1.94 in 2018Q2. The ratio fall, as 34 investment professionals started new and increased equity positions, while 18 sold and reduced their equity positions in Midsouth Bancorp Inc. The investment professionals in our database now own: 10.61 million shares, up from 10.19 million shares in 2018Q2. Also, the number of investment professionals holding Midsouth Bancorp Inc in top ten equity positions increased from 0 to 1 for an increase of 1. Sold All: 8 Reduced: 10 Increased: 27 New Position: 7.
Analysts expect FibroGen, Inc. (NASDAQ:FGEN) to report $-0.26 EPS on February, 26.They anticipate $0.01 EPS change or 3.70% from last quarter’s $-0.27 EPS. After having $-0.50 EPS previously, FibroGen, Inc.’s analysts see -48.00% EPS growth. The stock decreased 0.90% or $0.52 during the last trading session, reaching $57.56. About 382,400 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has declined 13.72% since February 14, 2018 and is downtrending. It has underperformed by 13.72% the S&P500. Some Historical FGEN News: 25/04/2018 – $GSK catching up quickly in HIF vs. $FGEN and $AKBA Positive results in house from first of three Ph3 for daprodustat in Japan; 07/05/2018 – RESOURCE CAPITAL FUND Vl L.P. ANNOUNCES ACQUISITION OF UNITS IN LOS ANDES COPPER LTD; 09/05/2018 – FIBROGEN 1Q LOSS/SHR 50C, EST. LOSS/SHR 51C; 18/04/2018 – The Andes Summit: More Than Ayahuasca – A Re-Validation of the Cultural Heritage of Ecuador’s Ancient Indigenous Wisdom; 13/03/2018 Announcing The First Andes Summit – Indigenous Wisdom-Keepers to Gather With People of The North to lnitiate a New Commitment to Earth Healing; 09/05/2018 – FibroGen 1Q Rev $31.9M; 12/04/2018 – $GLPG moving fast into #IPF Ph3 vs. $FGEN still at a snail’s pace; 21/05/2018 – FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic; 21/05/2018 – FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018; 14/05/2018 – FibroGen Closes Above 200-Day Moving Average: Technicals
Jacobs Asset Management Llc holds 3.31% of its portfolio in MidSouth Bancorp, Inc. for 1.17 million shares. Fj Capital Management Llc owns 795,000 shares or 1.36% of their US portfolio. Moreover, Thomson Horstmann & Bryant Inc has 1.22% invested in the company for 646,039 shares. The New York-based Basswood Capital Management L.L.C. has invested 1.16% in the stock. Mendon Capital Advisors Corp, a New York-based fund reported 675,789 shares.
More notable recent MidSouth Bancorp, Inc. (NYSE:MSL) news were published by: Zacks.com which released: “MidSouth Bancorp (MSL) Reports Q4 Loss, Tops Revenue Estimates – Zacks.com” on January 30, 2019, also Businesswire.com with their article: “Skechers India to Become Wholly-Owned Subsidiary of Skechers Footwear – Business Wire” published on February 12, 2019, Businesswire.com published: “MidSouth Bancorp, Inc. Announces Agreements with Significant Shareholders and Update to Board of Directors – Business Wire” on October 30, 2018. More interesting news about MidSouth Bancorp, Inc. (NYSE:MSL) were released by: Businesswire.com and their article: “MidSouth Bancorp, Inc. Reports Quarterly Dividends – Business Wire” published on November 29, 2018 as well as Nasdaq.com‘s news article titled: “New Vishay Intertechnology TMBS® Rectifiers in Low Profile SMF Package Save Space, Increase Power Density, and Improve Efficiency – Nasdaq” with publication date: January 30, 2019.
The stock decreased 0.44% or $0.05 during the last trading session, reaching $11.38. About 19,182 shares traded. MidSouth Bancorp, Inc. (MSL) has declined 14.32% since February 14, 2018 and is downtrending. It has underperformed by 14.32% the S&P500.
MidSouth Bancorp, Inc., a financial holding company, through its subsidiary MidSouth Bank, N.A., provides various community banking services and products to commercial and retail clients in the United States. The company has market cap of $189.38 million. The firm offers various deposit products, including interest-bearing money market and savings deposits accounts, interest-bearing and noninterest-bearing checking accounts, investment accounts, and NOW account deposits, as well as time deposits, such as certificates of deposits; and commercial and industrial, commercial real estate, and consumer loans, as well as other loans secured by real estate. It currently has negative earnings. It also provides cash management services; and electronic banking services comprising remote deposit capturing services, Internet banking, and debit and credit cards.
Among 3 analysts covering FibroGen (NASDAQ:FGEN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. FibroGen had 3 analyst reports since October 15, 2018 according to SRatingsIntel. The stock has “Outperform” rating by Leerink Swann on Monday, October 15. Citigroup upgraded FibroGen, Inc. (NASDAQ:FGEN) rating on Wednesday, December 19. Citigroup has “Buy” rating and $71 target. The stock of FibroGen, Inc. (NASDAQ:FGEN) earned “Buy” rating by Stifel Nicolaus on Monday, February 11.